Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

Next Previous
Trial Profile

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acipimox (Primary)
  • Indications Metabolic syndrome
  • Focus Pharmacodynamics

Most Recent Events

  • 13 Nov 2023 Results (n=16) assessing whether acipimox treatment will improve insulin-stimulated forearm blood flow (FBF) compared to placebo in volunteers with metabolic syndrome, presented at the American Heart Association Scientific Sessions 2023
  • 01 Oct 2019 Results published in the Obesity (Silver Spring, Md.)
  • 15 Aug 2013 Planned end date changed from 1 Dec 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top